We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Invesco Ltd | LSE:0UAN | London | Ordinary Share | BMG491BT1088 | INVESCO ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 28.61 | 3,870 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 5.84B | -333.7M | -0.7423 | -23.80 | 12.86B |
TIDMIRSH
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION (a) Full name of discloser Invesco Ltd. ---------------------------------------------------------------------- ------------------------- (b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. ---------------------------------------------------------------------- ------------------------- (c) Name of offeror/offeree in relation to whose relevant Amgen Inc securities this form relates Use a separate form for each offeror/offeree ---------------------------------------------------------------------- ------------------------- (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1) ---------------------------------------------------------------------- ------------------------- (e) Date position held/dealing undertaken 30/11/2022 For an opening position disclosure, state the latest practicable date prior to the disclosure ---------------------------------------------------------------------- ------------------------- (f) In addition to the company in 1(c) above, is the YES discloser also making disclosures in respect of any If YES, specify which: other party to the offer? Horizon Therapeutics PLC If it is a cash offer or possible cash offer, state "N/A" ---------------------------------------------------------------------- ------------------------- 2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) (Note 2)
Class of relevant security (Note 3) Common Stock US0311621009 -------------------------------------------------------- ------------------------------- Short Interests positions -------------------------------------------------------- ------------------ ----------- Number % Number % -------------------------------------------------------- ---------- ------ ------ --- (1) Relevant securities owned and/or controlled 10,466,336 1.961 -------------------------------------------------------- ---------- ------ ------ --- (2) Cash-settled derivatives -------------------------------------------------------- ---------- ------ ------ --- (3) Stock-settled derivatives (including options) and agreements to purchase/ sell -------------------------------------------------------- ---------- ------ ------ --- Total 10,466,336 1.961 -------------------------------------------------------- ---------- ------ ------ ---
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales Class of relevant Purchase/sale Number of Price per unit security securities (Note 5) ----------------- ------------- ----------- -------------- Common Stock Sale 123,594 286.40 USD ----------------- ------------- ----------- -------------- Common Stock Purchase 3,336 286.40 USD ----------------- ------------- ----------- -------------- Common Stock Purchase 54 279.57 USD ----------------- ------------- ----------- -------------- Common Stock Purchase 27 282.56 USD ----------------- ------------- ----------- -------------- (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price relevant description e.g. opening/ closing a long/ short position, increasing/ reference per unit security e.g. CFD reducing a long/ short position securities (Note 5) (Note 6) --------- ------------ ---------------------------------------------------------- ----------- --------- (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of Product Writing, purchasing, selling, varying Number Exercise Type Expiry Option relevant description e.g. call etc. of price per e.g. date money security option securities unit American, paid/ to which European received per unit option etc. relates (Note 6) --------- ---------------------- ------------------------------------- ----------- ---------- ---------- ------ ------------------ (ii) Exercise Class of Product Exercising/ Number of Exercise relevant description exercised securities price per security e.g. call against unit option (Note 5) --------- ------------ ----------- ----------- ---------- (d) Other dealings (including transactions in respect of new securities) (Note 3) Class of Nature of dealing Details Price per unit (if relevant e.g. subscription, applicable) security conversion, exercise (Note 5) --------- --------------------- ------- ------------------ 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer. Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" ----------------------------------------------- (b) Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. ------------------------------------------ (c) Attachments Is a Supplemental Form 8 attached? NO ---------------------------------- Date of disclosure 01/12/2022 ------------------- --------------- Contact name Philippa Holmes ------------------- --------------- Telephone number 01491 417447 ------------------- ---------------
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
(END) Dow Jones Newswires
December 01, 2022 10:33 ET (15:33 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Invesco Chart |
1 Month Invesco Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions